Technological projects portfolio
EVAC
Vaccine adjuvant
Investment: €808k
Scope: Healthcare
Scientific field(s): Biology and medicinal chemistry
Institution(s): Université de Versailles Saint-Quentin-en-Yvelines - CNRS
Development: Technology to be marketed
USE CASES
Aluminum salts are the adjuvants of reference for toxoid vaccines. They are necessary to trigger strong, long-lasting immunization. However, these adjuvants are not broken down in the human body and leave permanent deposits: internal tattoos.
The fear is that these deposits could be associated with undesirable side effects, which has led to significant mistrust of vaccines and the risk of a regression in vaccination coverage.
Despite intensive research, the alternatives that have been developed still do not present a risk-benefit ratio as advantageous as that of the aluminum adjuvants.
ADVANTAGES
The EVAC project aims to develop absorbable adjuvants. They are progressively broken down in the body, which makes it possible to initiate an immune response before the adjuvant has dissolved, and therefore prevent the formation of deposits by accumulation.
APPLICATIONS
The EVAC technology is intended for the inactivated and toxoid vaccine markets, where adjuvants are required.
These vaccines represent ¾ of all pediatric vaccines: a decrease in potential side effects and improved trust in these vaccines is crucial to ensure maximum vaccination coverage for most childhood diseases.